Vireo Launches CBN Product into New York Medical Cannabis Market – New Cannabis Ventures

Vireo Health Launches “Midnight” Cannabis Brand

– The new brand recently launched in New York as a softgel product –

– Product line will be expanded to include vaporizers and other product formats in 2021 –

MINNEAPOLIS, Oct. 15, 2020 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO, OTCQX: VREOF), the science-focused, multi-state cannabis company with active operations in exclusively medical-only markets and licenses in seven states and the Commonwealth of Puerto Rico, today announced the launch of a new cannabis-based brand, called Midnight.

The Midnight brand launched at Vireo’s four medical dispensaries in New York and is also available via wholesale channels to other licensed dispensaries in New York.

Midnight products are ideally formulated with a balanced blend of multiple cannabinoids including THC, CBD, and CBN. Later this year, Midnight will also be made available as a vaporizer product and the Company expects to expand the Midnight brand with additional product formats and new formulations in 2021. The product line is also expected to be made available in several of Vireo’s other markets later in 2021. All of these events are subject to regulatory approval.

Vireo’s physician-led research teams continue to create innovative products that reflect targeted needs of cannabis consumers. The Midnight product line highlights CBN, a novel cannabinoid with low psychoactivity and evidence supporting its potential role in the calming effects of specific cannabis plants. Midnight products likely have significant market potential across